Noxopharm Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Gisela Mautner

Chief executive officer

AU$491.6k

Total compensation

CEO salary percentage	83.4%
CEO tenure	2.4yrs
CEO ownership	n/a
Management average tenure	3.5yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gisela Mautner's remuneration changed compared to Noxopharm's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$492k	AU$410k	-AU$15m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$1m	AU$201k	-AU$19m

Compensation vs Market: Gisela's total compensation ($USD326.95K) is below average for companies of similar size in the US market ($USD697.54K).

Compensation vs Earnings: Gisela's compensation has been consistent with company performance over the past year.

CEO

Gisela Mautner

2.4yrs

Tenure

AU$491,562

Compensation

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gisela Mautner	CEO, Executive MD & Director	2.4yrs	AU$491.56k	no data
Shawn Van Boheemen	Chief Financial Officer	5.3yrs	no data	no data
Jeanette Bell	Chief Operating Officer	4.5yrs	no data	no data
John Wilkinson	Chief Scientific Officer of Oncology	2.5yrs	no data	no data
Olivier Laczka	Chief Scientific Officer of Inflammation	2.5yrs	no data	no data
David Franks	Company Secretary	7.5yrs	AU$16.49k	no data

3.5yrs

Average Tenure

Experienced Management: NOXO.F's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gisela Mautner	CEO, Executive MD & Director	no data	AU$491.56k	no data
Frederick Bart	Non-Executive Chairman	4.2yrs	AU$45.00k	2.57% A$ 330.5k
Peter Marks	Non-Executive Deputy Chairman	8.3yrs	AU$60.00k	0.31% A$ 39.6k
Boris Patkin	Non-Executive Director	4.3yrs	AU$56.69k	0.22% A$ 27.7k

4.3yrs

Average Tenure

70yo

Average Age

Experienced Board: NOXO.F's board of directors are considered experienced (4.3 years average tenure).

Noxopharm Management

Management criteria checks 4/4

Key information

Recent management updates

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Recent updates

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age